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Cholecystokinin ( CCK) has well-documented anxiogenic effects in animals and normal people, 
and panicogenic effects in patients with panic disorder, but little is known about its neuroendo- 
crine profile. We examined neuroendocrine responses to intravenous infusions of pentagustrin, 
a selective CCK-B receptor agonist, in 10 patients with panic disorder and 10 normal control 
subjects. Pentagastrin potently activated the hypothalamic-pituitary-adrenal (HPA) axis, but 
did not release growth hormone or any of several vasoactive peptides (neurokinin A, substance 
P, vasoactive intestinal peptide). The HPA axis response was unrelated to increases in symp- 
toms. Panic patients did not differ from controls in neuroendocrine responses to the CCK 
agonist. Differential sensitivity to novelty stress accounted for the only patient-control differ- 
ences in neuroendocrine profiles. The data suggest that CCK may help modulate normal HPA 
axis activity, but its anxiogenic effects are unrelated to its stimulatory effects on the HPA axis. 
Pentagastrin provides a safe and readily available probe for further study of CCK receptor 
systems in humans. 
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Introduction 
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neurotransmitter in the brain (Rehfeld 1985). Its receptors 
are widely distributed throughout the central nervous sys- 
tem (CNS), with high densities in the hypothalamus, limbic 
system, basal ganglia, hippocampus, and cortex (Woodruff 
and Hughes 1991). CCK is co-localized with or interacts 
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dopaminergic (Crawley 1991), noradrenergic (Beresford et 
al 1988; Kane]mki et al 1989), GABAer~c (gamm_a a_m_iino- 
butyric acid) (Kaneyuki et al 1989; Sbeehan and de Beller- 
ocbe 1983), and serotonergic (Brodin et al 1989; Stallone et 
al 1989) neurotransmitter systems. It may co-modulate hy- 
pothalamic-pituitary-adrenal (HPA) axis (Abelson et al 
1991) and hypothalamic-pituitary-somolrophic (lIPS) axis 
activity (Karashima et al 1984; Spencer et al 1991). Its 
functional roles are not yet fully defined, but it appears to 
mediate anxiety (Singh et al 1991) and it may participate in 
satiety (Silver and Morley 1991), alcohol satiation (Kul- 
kosky et al 1989), psychosis (Crawley 1991), nociception 
(Baber et al 1989), and drug withdrawal (Hughes et a11991; 
Singh et al 1991). 
Despite a neuroanatomy, neurophysiology, and func- 
tional significance that establish CCK as a neurotransmitter 
of potential importance in a number of psychiatric dis- 
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orders, it has received relatively little attention in the psy- 
chiatric research literature. The dearth of clinical psychiat- 
ric research on CCK likely results from the early focus of 
basic research on its gastrointestinal functions and from a 
lack of CCK probes that can be used in humans. Recent 
identification of two types of CCK receptors (CCK-A and 
CCK-B) and increased awareness of their distributions 
within both the peripheral and central nervous systems, 
however, have greatly expanded the range of potential ther- 
apeutic applications of CCK active drugs (Dethloff and De 
La Iglesia 1992) and has led to increased commercial inter- 
est in agents with subtype-specific receptor activity and 
with psychiatric applications. New antagonists with in- 
creased specificity for the CCK-B receptor, which is the 
predominant subtype within the central nervous system, 
have now shown therapeutic potential in animal models of 
anxiety disorders and drug abuse (Woodruff and Hughes 
1991). These new agents and the possibility that CCK may 
play a key role in alerting/alarm circuits (Hughes et al 1991) 
make more detailed understanding of human CCK systems 
of great importance. Cross-species variations in the distri- 
bution and function of CCK receptors (Woodruff and 
Hughes 1991) make it difficult, however, to generalize to 
humans from the animal literature. The availability of selec- 
tive CCK-B receptor antagonists for human research and 
their use in conjunction with already available selective 
agonists will be critical to expanding what we know about 
CCK receptor function in humans. 
Pentagastrin is a 5-amino acid synthetic peptide that has 
been used as a provocative agent in tests for endocrine 
tumors (Ahlman et al 1985; O'Connell et al 1990; Oberg et 
al 1989; Vinik et al 1990). It is a highly selective CCK-B 
receptor agonist (Woodruff and Hughes 1991 ) that offers an 
established and readily available neuroendocrine probe for 
human use. We initiated study of pentagastrin infusions in 
patients with panic disorder because the relevance of the 
CCK-B receptor to anxiety disorders in general, and panic 
in particular, has been clearly suggested by both animal a~ad 
human studies (Bradwejn et al 1991; Singh et al 1991). The 
selective CCK-B receptor agonist, CCI~, is now well- 
established as a panicogenic agent (Bradwejn et al 1991) 
and CCK-B receptor antagonists may provide a novel ap- 
proach to the treatment of panic disorder (Bradwejn et al 
1993). In a separate article we report that pentagastrin is 
comparable to CCK4 as a panicogenic agent (Abelson and 
Nesse 1994). The present report examines the neuroendo- 
crinology of the CCK-B receptor system in humans, focus- 
ing on pentagastrin's effects on neuroendocrine systems 
that have been implicated in the pathophysioiogy of panic 
disorder. Because blunted corticotropin [adrenocorticotro- 
pic hormone (ACTH)] responses to corticoh-opin-releasing 
hormone (CRH) provide evidence of an HPA axis abnor- 
mality in panic (Roy-Byrne et al 1986) and because CCK 
agonists can stimulate ACTH release (Degli Uherti et al 
1983), ACTH and cortisol responses are of ~ inte~- 
est. Panic patients also have blunted growth ~ (GH) 
.re~po_.n_~es to c!onidine challenge, which ~ an hy- 
pothesized abnormality in ~ i n e r g i c  systems (Abel- 
son et al 1992), so we also examir~l GH ~ catecbolamine 
responses. Finally, it remains unclear if anxiety ~ ~ 
CCK is due to central or peripheral effects. Pentagastrin can 
stimulate peripheral release of vasoacfive peptides (Ahlman 
et ai 1985; Oberg et al 1989; Vinik et al 1990), which could 
mediate or mimic peripheral somatic symptoms of panic. 
We therefore also examined vasoactive intestinal ~ 
(VIP), neurokinin A (NKA), and substance P. Previously 
published preliminary analyses of a subset of our ACTH a ~  
cortisol data (Abelson et al 1991) demonstrated that penta- 
gastrin stimulated the release of ACTH and cortisol and 
suggested that panic patients might have increased HPA 
axis responsivity to pentagastrin. These analyses were 
based on very small samples and were not controlled for 
placebo responses. We now report the full ~ y s e s  of all 
neuroendocrine data collected in a two phase study. 
Methods 
Subjects 
All 20 subjects gave informed consent and were medically 
healthy as determined by medical history, physical exami- 
nation, and screening laboratory tests. AH subjects, includ- 
ing controls, were evaluated using a Structured Clinical 
Interview for DSM-III-R (Spitzer and Williams 1986). 
Panic patients met DSM-HI-R criteria for panic disorder 
(n = 4) or panic disorder with agoraphobia (n = 6). They did 
not meet criteria for current (past 6 months) major depres- 
sion or substance abuse and did not have any history of 
primary depression or psychosis. Control subjects were re- 
cruited from the community using newspaper advertising. 
They were age matched and gender matched to the patients 
and did not meet criteria for any Axis I disorder. All women 
(n = ! 6, 8 in each group) had normal menstrual cycles and 
were studied within 10 days of onset of menses (to insure 
they were not pregnant and to avoid the effects of the pre- 
ovulatory estrogen surge on hormonal measures). All su~ 
jects were free of psychotropic medication for at least 2 
weeks prior to study. Only two patients had received daily 
pharmacological treatmeW, for panic disorder in the months 
prior to study (one was taking buspirone and another alpra- 
zolam), but both discon*~inued their medication more than a 
month before the study. A third patient had used occasional 
doses of lorazepa-m (2-3 times/week) up until 3 weeks prior 
to study. 
Design and Procedures 
The study was conducted in two phases in a Clinical Re- 
search Center (CRC). In the first phase, five patients and 
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five controls were each admitted once and given a single 
infusion of pentagastrin. Blood sampling at 30, 15, and 1 
min before infusion, and approximately 1,3, 5, 7, 10, 15, 20, 
30, 45, and 60 min after infusion allowed detailed initial 
examinations of hormonal response patterns. These initial 
results allowed reduced sampling frequency in phase 2, 
which permitted addition of a placebo infusion without 
exceeding blood volume limits. An additional five patients 
and five controls were recruited. Phase 2 subjects were 
admitted on two occasions a week apart, receiving a saline 
placebo infusion on visit 1 and pentagastrin on visit 2 (ad- 
ministcred in a single-blind fashion). Samples were ob- 
tained at 30 and I min before infusion, and 3, 5, 10, 20, 30, 
and 45 min after infusion. We used a fixed order of adminis- 
tration, with active substance second, because panic pa- 
tients are especially reactive to novel situations and there- 
fore stress-reactive measures are likely to be closer to true 
baselines during a second visit to the CRC. Phase 2 was 
identical to phase 1 except for the addition of the placebo 
infusion and the reduced blood sampling frequency. 
Subjects were admitted to the CRC the night prior to 
study. They were awakened at 7:30 AM. At 8 AM an indwell- 
ing heparin lock catheter was inserted into an antecubital 
vein. Baseline blood samples were drawn between 8:30 AM 
and 8:59 AM. At 9 AM saline placebo or pentagastrin (com- 
mercially available as Peptavlon, Wyeth-Ayerst Laborato- 
ties, Philadelphia, PA) was infused into the heparin lock, in 
view of the patient, in less than 1 rain. The pentagastrin dose 
was 0.6 Ixg/kg, in a saline vehicle of less than 1 ml. Blood 
samples were drawn into chilled tubes according to the 
schedule described above. Samples were spun, separated, 
and frozen at -70°C within 30 min of being drawn. Details 
of instructions given to subjects and monitoring of symptom 
and cardiovascular measures are described elsewhere 
(Abelson and Nesse 1994). 
Biochemical Assays 
Samples for ACTH, GH, substance P, and NKA were drawn 
into tubes containing ethylenediaminetetraacetic acid 
(EDTA). ACTH was measured by radioimmunoassay, with 
a sensitivity of 6 pg/ml and intraassay and interassay coeffi- 
cients of variation (CVs) of less than 10%. GH, substance P, 
and NKA were measured by a double-antibody radioimmu- 
noassay. For GH the sensitivity was 0.8 ng/ml and intraas- 
say and interassay CVs were 18.3% and 14.5%, respec- 
tively. For substance P the sensitivity was 10 pg/ml and 
intraassay and interassay CVs were 1.4% and 15.8%, re- 
spectively. For NKA the sensitivity was 0.15 pg/ml and CVs 
were less than 10%. Samples for cortisol and catechola- 
mines were drawn into tubes containing heparin. Cortisol 
and catecholamines were measured by high-performance 
liquid chromatography. For cortisol the sensitivity was 0.1 
t~g/dl and CVs were less than 6%. For epinephrine, nor- 
epinephrine, and dopamine the sensitivities were 17 pg/ml, 
11 pg/ml, and 22 pg/ml, respectively. The CVs were all less 
than 12%. VIP was drawn into tubes containing EDTA and 
aprotinin. It was measured using radioimmunoassay with a 
sensitivity of 11 pg/hml and intraassay and interassay CVs 
of 2.5% and 21%, respectively. 
DataAnalyses 
Two sets of three-way, repeated measures analyses of var- 
iance (ANOVAs) were used for the primary analyses. In 
order to confirm, with placebo-controlled data, that penta- 
gastrin releases ACTH and cortisol, the initial analyses used 
phase-2 data alone to examine the effects of drug (pentagas- 
trin versus placebo), diagnosis (patients versus controls), 
and time. The effects of pentagastrin on hormone release are 
reflected in the drug effect and the drug-by-time interaction 
in these analyses~ The drug-by-time-by-diagnosis interac- 
tion reflects the degree to which patients and controls re- 
sponded differently to the 2 conditions (placebo versus pen- 
tagastrin) and thus tests whether patients were more 
sensitive than controls to specific pharmacological effects 
of the drug. 
The second set of analyses ufifized pentagastrin-day data 
from both phases in three-way ANOVAs (phase-by-diag- 
nosis-by-time). Because the entire sample was included, 
these analyses had greater power to detect patient-control 
differences. Phase was included as a between-group main 
effect in these analyses to determine if prior experience with 
the infusion procedure (placebo session) altered responses 
to pentagastrin for phase-2 subjects. Patient-control differ- 
ences are reflected in the the effect of diagnosis and its 
interactions. The time-by-diagnosis interaction reflects pa- 
tient-control group differences in responsivity to pentagas- 
trin. Time is a within-group factor, utilizing baseline and 
postinfusion measures and reflecting response to the infu- 
sion. 
A l l  h n r m n n ~  d a t a  ~ a ©  l n ~ _ t ~ n e f ~ a A  , ~ .  • . . . .  ! . . , : , ,  
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to normalize distributions. In analyses that utilized data 
~ m  both phase 1 and 2 (~CTH, co . so l ,  GH, and NK~), 
only time points at which samples were collected in both 
phases were included. When significant effects were found 
in the primary ~ O V ~ s ,  follow-up ~-tests were used to 
~mher dissect the findings. ~dditional comparisons were 
carried out on total preinfusion and postinfusion hormone 
secretion, as measured by area under the preinfusion and 
postinfusion curves (AUCs) calculated by trapezoidal ap- 
proximation, and on peak responses~ calculated by subtract- 
ing mean baseline levels from the postinfusion peak level. 
R e s u l t s  
One control subject in phase I had a resting norepinephrine 
level of over 1000 pg/ml, suggesting a neuroendocrine ab- 
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Figure !. Corticotropin (ACTH) responses to pentagastrin (upper 
graph) and placebo (lower graph) in patients with panic disorder 
(closed symbols) and controls (open symbols). Subjects in phase I 
(squares) received only pentagastrin infusion. Subjects in phase 2 
(circles) received both pentagastrin and placebo. Group means and 
SEMs are plotted at each sampling point before and after infusion 
(arrows). The x-axis was plotted with equal distance between 
sampling points rather than scaled to actual time to make the 
graphs more readable. See text for analyse. 
normality, and he was dropped from all analyses. Charac- 
teristics of the patient and control groups have been 
presented elsewhere (Abelson and Nesse 1994). 
A CTH and Cortisol 
ACTH responses to pentagastrin (phases 1 and 2) and pla- 
cebo (phase 2) are presented in Figure 1. Analysis of pla- 
cebo-controlled data (phase 2 alone, see Table 1) confirmed 
the striking effect ofpentagastrin on ACTH secretion that is 
evident in the graphs. ACTH levels doubled following pen- 
tagastrin infusion but did not respond at all to placebo (ef- 
fects of drug, time, and their interaction were all highly 
significant). There were no significant differences between 
patients and controls in these placebo-controlled analyses, 
though the drug-by-diagnosis interaction approached sig- 
Table I. Diagnosis (Patients venus Conuols) by Drug 
(Pentagastrin versus Placebo)by T~me ANOVAs of ~ 
Connolled Phase 2 Data for Conk-ouo~n (ACTH), ~ ,  and 
Growth Hormone (GH) 
ACIH Cettisol ~ 
F p F p F p 
Diagnosis I °04 NS 0,82 NS ~.5 0.0~ 
Drag 2"/.62 0,~ I.~I NS I~ NS 
T i ~  12,16 0 . ~ i  4,74 0 , ~ 3  L53 NS 
~ g - b y ~  16.31 0 . ~ 1  1233 0 ~ 1  l . ~  NS 
~ i s - b ~ - f i ~  0.39 NS 0~5 NS 4.15 0 , ~  
~ i s - b y  ~ g  4.31 0 . ~  0.03 NS 0.4 ! NS 
~ n ~ i s - b y ~ g -  
by - f i~  0 . ~  NS 0.41 NS I . ~  NS 
nificance (Table 1). This trend appears due to placebo day 
differences between patients ~ controls that disappeared 
under the influence of pentagastrin. On placebo day patients 
had significantly higher peak ACTH levels [patient mean = 
34.2 _+ 14.8; control mean = 17.4 -+ 8.26; t(8) = 2.59, p = 
0.032] and nearly significantly higher toual ACTH secretion 
[patient mean = 1931 -+ 940; contr~l mean = 1070 +_ 459; 
t(8) = 2.1, p = 0.066], compared to controls; ~ t  the groups 
did not differ in peak ACTH levels following pentagastrin 
[patient mean = 8.4.8 _+ 56.45; control mean = 106.4 _+ 
63.87; t(8) = 0.5, p = 0.63] and they had nearly identical 
levels of total ACTH secretion (AUC) on pentagastrin infu- 
sion day [patient mean = 3045 _+ 1648; control mean = 
3170 + 1907;t(8)=0.1,p=0.94]. 
Patient-control differences should be more evident in 
analyses of pentagastrin-day data from the entire sample 
(phases combined), but the overall ANOVA (Table 2) re- 
vealed no significant ACTH differences between patients 
and controls. The highly significant effect of time in this 
analysis again reflects the striking rise in ACTH following 
pentagastrin infusion. Paired t-tests showed ACTH levels to 
be significantly elevated above baseline levels at 3, 5, 10, 
20, and 30 min after infusion It(18) = 5.4, p = 0.0001; t(l 8) = 
5.6, p = 0.0001; t(18) = 5.0, p = 0.0001; t(18) = 3.5, p = 
Table 2. Diagnosis (Patients versus Controls) by Phase (! versus 2) 
by Time ANOVAs of Corticotropin (ACTH), Cortisol, and Growth 
Hormone (GH) Responses to Pentagastdn for All Subjects 
ACTH Cortisol GH 
F p F p F p 
Diagnosis 1.31 NS 0.31 NS 4.85 0.048 
Phase 7.25 0.02 0.17 NS 5.07 0.04 
Time 23.26 0.0001 18.52 0.0001 1.18 NS 
Diagnosis-by-phase 1.20 NS 3.83 0.07 i.07 NS 
Diagnosis-by-time 0.42 NS 0.19 NS ! .2 ! NS 
Phase-by-time 3.95 0.0007 1.34 NS 0.92 NS 
Diagnosis-by-phaseo 
by-time 0.35 NS 0.37 NS !. ! 5 NS 
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0,003; and z(18) = 2.8, p = 0.011, respectively]. There were 
significant differences between phase I and phase 2 (re- 
flected in the phase effect and phase-by-time interaction), 
primarily because of elevated baseline ACTH levels in 
phase 1. For all subjects, preinfusion ACTH secretion 
(AUC) was significantly higher in phase 1 than in phase 2 
It(17) = 4.9, p = 0.0001]. This phase effect on baseline 
ACTH levels remained significant for patients and controls 
analyzed separately It(8) = 3.7, p = 0.006; and z(7) = 3.3.59, 
p = 0.009, respectively]. A phase effect on poszinfusion 
ACTH secretion was present only.f.or patients [phase 1 > 
phase 2, z(8) = 2.51, p = 0.036 for patients; z(7) = 0.47, p = 
0.65 for controls]. Phase 2 patients look identical to controls 
in either phase on post-pentagastrin secretion, whereas 
phase I patients hypersecreted AC'~H before and after infu- 
sion (see Figure 1). 
Because of the striking effect of phase on baseline ACTH 
we further examined baseline levels in a two-way ANOVA 
that utilized mean baseline ACTH during subjects' first visit 
to the CRC (first and only visit for phase 1 subjects, first of 
two visits for phase 2 subjects) as the dependent variable. 
The main effects examined were diagnosis and phase. Both 
main effects were significant. For all subjects, during their 
first experience with the infusion paradigm preinfusion 
ACTH levels were higher in phase 1 than phase 2 [F(I, 15) = 
32.7, p = 0.0001 ]. Regardless of phase, patients had higher 
pre-infusion ACTH levels than controls during the first 
CRC visit [F(1,15) = 8.2, p = 0.012]. The phase-by-diagno- 
sis interaction was not significant [F(1,15) < 1, p = 0.99]. 
Cortisol responses to pen~:agastrin (phases 1 and 2) and 
placebo (phase 2) are presented in Figure 2. Analysis of 
placebo-controlled cortisol data (phase 2 alone, see Table 1) 
confirmed the striking effect of pentagastrin on I-IPA activ- 
ity that was seen in the ACTH analyses and is evident in the 
cortisol graphs. A normal diurnal decline in cortisol levels is 
seen following placebo infusions but a clear rise is seen 
f~bwing  pentagas~n infusions (effect of time and the 
drug-by-time interaction were both highly significant). 
There were no significant differences between patients and 
controls in placebo-controlled analyses of cortisol data. 
Analyses of pentagastrin-day cortisol data from the com- 
bined sample (Table 2) also revealed no significant differ- 
ences between patients and controls. There was a highly 
significant effect of time in this analysis, again reflecting the 
striking HPA response to pentagastrin infusion. Cortisol 
levels declined from 30 min before infusion to 3 rain after 
infusion, then rose to a peak at 20 rain after pentagastrin. 
Paired t-tests showed cortisol levels to be significantly 
below b~eline levels at 3 rain after infusion [t(18) = 4.9, p = 
0.0001 ] and significantly elevated above baseline levels at 
10, 20, and 30 rain after infusion [t(18) = 5 . l , p  = 0.0001; 
z(i8) = 6.0,p = 0.0001; and z(18) = 3.9, p = 0.001, respec- 
tively]. 
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Figure 2. Cortisol responses to pentagastrin (upper graph) and 
placebo (lower graph) in patients with panic disorder (closed sym- 
bols) and controls (open symbols). Subjects in phase 1 (squares) 
received only pentagastrin infusion. Subjects in phase 2 (circles) 
received both pentagastrin and placebo. Group means and SEMs 
are plotted at each sampling point before and after infusion 
(arrows). The x-axis was plotted as in Figure 1. See text for analy- 
ses. 
"Ihe phase effect was less evident in the cortisoi data than 
in the ACTH data, but there was a trend towards a signifi- 
cant diagnosis-by-phase interaction (Table 2). This interac- 
tion reflected the patients' higher cortisol levels throughout 
phase 1 as compared to phase 2, whereas controls had higher 
levels throughout phase 2 than they did in phase I. 
To search further for possible patient-control group dif- 
ferences, patients and controls were directly compared on 
preinfusion and postinfusion cortisol secretion, and on peak 
response, first for the total groups and then separately for 
each phase. The total patient group (n = 10) did not differ 
from the total control group (n = 9) on any of these measures 
(p > 0.60 for each). In phase I patients bad greater postpen- 
tagastrin cortisol secretion It(7) = 2.8, p = 0.026] and higher 
cortisol peaks It(7) = 2.8, p = 0.025] than did controls, but 
Responses to Pentagastrin in Panic ~ PSY(:m~TZtY ~ 
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did not differ from controls in baseline secretion [t(7) = 1.8, 
p = 0.12]. In phase 2 patients and controls were nearly 
identical on all 3 measures (p > 0.20 for each). 
Pearson product-moment correlation coefficients were 
used to examine relationships between ACTH and c o ,  sol 
responses and baseline levels. Baseline ACTH and ba~:line 
cortisoi were significantly related to each other (r-- 0.6, p -- 
0.006) and postpentagastrin ACTH secretion (AUC) was 
significantly related to basefine ACTH secretion ~r = 0.6, 
p = 0.005). Postpentagastrin ACTH secretion was not re- 
lated to baseline cortisol secretion (r = 0.2, p = 0.51) and the 
ACTH peak response was not related to either baseline 
cortisol (r = 0.1, p = 0.58) or baseline ACD~ (r = 0.2, p = 
0.50), however. The relationships between both postpenta- 
gastrin ACTH secretion and ACTH peak response and base- 
line cortisol levels remained small and nonsignificant for 
patient and control groups examined separately. 
Pearson correlations were also used to search for rela- 
tionships between ACTH secretion a~ld baseline and postin- 
fusion symptom levels. There were no relationships be- 
tween the number of symptoms, total symptom intensity, 
and anxiety levels experienced i-,efore or after pentagastrin 
and either the peak ACTH response or total postinfusion 
ACTH secretion, for the total group and for controls exam- 
ined separately (r < 0.3, p > 0.23 in every case). When 
panic patients were examined separately there were inverse 
relationships (trends) between prepentagastrin anxiety rat- 
ing and postpentagastrin ACTH secretion (r = -0.6, p = 
0.059); and between the number of symptoms experienced 
in response to pentaga,~trin and peak ACTH response (r = 
-0.6,p = 0.07). Those ?anic patients who were most anxious 
prior the infusion and experienced the greatest number of 
symptoms in respo~.se to it tended to have smaller ACTH 
responses. A trend in the opposite direction was seen for the 
total group (patier, ts and controls) receiving placebo (n = 
10), with a positive relationship between the number of 
symptoms experienced after the infusion and peak ACTH 
levels (r = 0.6,/', = 0.05). 
The data were also examined for relationships between 
the HPA axis and clinical or demographic variables. We 
detected no effects of age, weight, age of panic onset, dura- 
tion of illness, ~3anic attack frequency, or presence or ab- 
sence of agorapt, obia on any measure of HPA axis activity 
or responsivity to pentagastrin. There were too few men in 
the study to allow assessment of gender effects. 
G r o w t h  H o r m o n e  - 
GH responses to penta~astrin (phases I and 2) and placebo 
(phase 2) are presented in Figure 3. One control subject and 
one patient were dropF,~d ~om GH analyses due to elevated 
baseline GH levels (>5 ttg~L). Another patient was dropped 
due to insufficient sample volumes. In contrast to analyses 
of ACTH and cortisol data, analysis of placebo-controlled 
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GH data revealed no response to pentagastrin (Table 1). 
Patient-control differences are suggested by the nearly sig- 
nificant effect of diagnosis and the significant diagnosis-by- 
time interaction. The interaction effect was due to the rising 
GH levels seen at 30 and 45 rain following both placebo and 
pentagastrin in controls, while patients' levels remained fiat 
(see Figure 3). 
Patient-control differences are slightly more evident in 
analyses of pentagastrin-day data from the combined sam- 
ple (Table 2). Here the main effect of diagnosis was signifi- 
cant. Patients had lower overall mean GH levels than con- 
trois (1.02 _+ 1.22 ~g/L versus 1.90 _ 2.04 I~g/L). The main 
effect of phase also reached significance; overall GH levels 
were lower in phase 1 than phase 2 (0.87 _+ 0.62 ~g/L versus 
2.04 _+ 2.22 p.g/L). T~e lack of any time effects confirms the 
lack of GH response to pentagastrin infusion. GH levels 
were extremely low throughout the procedures for nearly all 
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subjects. There were few secretory spikes seen and a possi- 
ble response to pentagastrin was seen for only one subject, a 
control in phase 2 who went from a baseline of 1.7 l~gFLjust 
prior to pentagastrin infusion to a peak of 13.3 Ixg/L at 10 
rain after pentagastrin. 
Overall mean GH levels were inversely related to penta- 
gastrin day baseline ACTH levels (r = -0.8, p = 0.0002). 
This relationship remained strong for patients and controls 
examined separately (r < -0.8, p < 0.05 for both) and for 
phase I and phase 2 data examined separately (r = -0.7, p < 
0.06 for both). 
Neurokinin A 
Samples fc;r NKA assay were available from all 10 subjects 
in phase 2, but only from 3 controls and 4 patients fror- 
phase 1. The two three-way ANOVAs produced only a 16o 
significant main effect of phase [F(I,13) = 20.299, p = 1,s0 
0.0006], and a nearly significant effect of diagnosis [F(i,  i 3 ) ~ : :  
= 4.221, p = 0.0611. No effects involving time and no 
interaction effects approached significance. NKA levels [[ ao 
were higher in phase 1 than in phase 2 and tended to be ~ 
higher in patients than in controls. These differences ap- ~ so 
peared primarily in baseline levels on pentagastrin day. m ~0 
There was no discernable response to pentagastrin. Baseline ~ 
NKA levels on pentagastrin day were positively related to 
baseline ACTH levels (r = 0.7, p = 0.001). 
Catecholamines, VIP, cnd Substance P 
Data on additiong.! hormones are only available from phase 
l, so the main analysis was two-way ANOVA (diagnosis- 
by-time). Useful data was not available from all subjects 
and the resultant small sample sizes made patient-control 
comparisons unlikely to be meaningfully interpretable. Our 
interest centered on "time" effects, which might reflect 
responsivity to the infusion. The main effect of time was 
significant in the two-way ANOVAs for ~inephrine 
[F(9,45) = 2.5, p = 0.019] and VIP [F(12,72) = 2.0, p = 
0.034], approached significance for norepinephrine 
[F(9,63) = 1.978, p = 0.057], and was not significant for 
dopamine [F(9,54) = 0.679, p = 0.72] and substance P 
IF(! 2,84) = 1.2, p = 0.27]. Epinephrine showed a striking, 
consistent, and brief response, with a spike present l min 
after infusion but gone at 3 min after infusion in six of seven 
subjects (see Figure 4). Epinephrine levels were signifi- 
cantly elevated above baseline levels only at the + l min time 
point It(6) = 3.9, p = 0.008]. VIP levels fell slightly over the 
baseline period to a nadir at 1 rain after infusien, and then 
rose to a peak that was inconsistently maintained from 7 to 
20 min after infusion before falling again. VIP levels at 7 
and 20 min after infusion were significantly elevated above 
the +l  rain trough It(7) > 2.6,p < 0.05 for both]. The nearly 
significant effect of time for NE was due to slowly rising 
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Figure 4. Epinephrine responses to pentagasu-in in seven subjects 
from phase l. Group means and SEMs are preseated in the upper 
graph, lnd;.vidual subjects' data are presented in the lower graph 
(controls are represented by solid h'nes and patients by broken 
lines). The point of infusion is marked with a-rows. The x-axis was 
plotted with equal distance between sampling points rather than 
scaled to actual time to make the graphs more readable. See text for 
analyses. 
levels from the beginning to end of the sampling period with 
no consistent response to the infusion itself. 
Epinephrine levels at l min after infusion (peak) "vere 
strongly related to baseline heart rate ( r=  0.78,p < 0.05) but 
not to postinfusion heart rate or to blood pressure. There 
were no significant relationships between epinephrine and 
any measures of symptoms or HPA axis activity. 
Discussion 
CCK and HPA Axis 
As far as we know, this data provides the first placebo-con- 
trolled confirmation of an early report that pentagastdn 
potently activates the HPA axis in humans (Degli Uberti et 
al 1983). Data from our enlarged samples support our earlier 
impression (Abelson et al 199 l) that this response is a direct 
pharmacological effect and is not mediated by anxiety 
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symptoms or a nonspecific stress response. We found no 
relationship between the ACTH or cortisol ~sponses to 
pentagastrin and the symptoms produced. After placebo 
infusion there was a positive correlation b.~tween ACTH 
levels and the number of symptoms experie~ced, indicating 
that HPA activity is sensitive to nonspecif, c stressors in our 
experimental paradigm, but under the apparently potent 
stimulus of pentagastrin this positive association disap- 
pears. There is even a hint that for par, ic patients it inverts; 
the patients with higher levels of anticipatory anxiety and 
more symptomatic responses to pe~tagastrin tended to have 
smaller ACTH responses. Further support for the specificity 
of the ACTH response is provided by the lack of GH or 
NKA responses. GH is knowa to he a stress responsive 
hormone (Breier et al 1988), but did not respond to penta- 
gastrin despite the substanti~ subjective distress produced. 
NKA levels were strongly related to ACTH levels prior to 
the pentagastrin infusion, perhaps linked by shared respon- 
sivity to the stress of the procedure, but NKA levels did not 
rise following the it, fusion, indicating pharmacological 
specificity in pentagastrin's ~'.bifity to release ACTH. It is 
possible that pentagastrin has direct inhibitory effects on the 
release of GH (see below) or NKA, which block a stress 
response that might otherwise be seen, but this is still con- 
sistent with ph~a'macologically specific neuroendocrine ef- 
fects. 
Our data ~e consistent with the few other studies that 
have examined CCK-HPA interactions in humans. In the 
only other published study of HPA response to pentagastrin 
in humans (Degli Uberti et al 1983), a dose of 0.5 Itg/kg 
produced ACTH and cortisol response curves nearly identi- 
cal to ours. Cerulein, a naturally occurring CCK agonist, 
stimulates ACTH and cortisol responses in humans nearly 
identical to those eficited by CRH (Sp~ith-Schwalhe et al 
1988). Elevation in cortisol ~'ollowing CCK4 infusion has 
also been reported (de Montigny 1989). 
Neuroanatomical and pharmacological data from basic 
s~,udies are consistent with our findings and support a physi- 
ological role for CCK in modulating HPA axis activity. 
CCK/gast~ns are found within the pituitary and in parvo- 
cellular neurons in the paraventricular nucleus (PVN~ in ~e 
hypothatamus and are co-localized with ACTH and CRH 
(Larsson ~ v  Rehfeld 1981; Rehfeld 1978; ReIffeid and 
Larsson |98~; Rehfeld et al 1987: Vanderhaeghen et al 
1985). CCK in the hypothalamus is regulated by adrenal 
activity (Mezey et al 1986). CCK stimulates ACTH and 
13-en~orphin release in vitro as well as in vivo (Matsumura 
et al 1983; Mezey et al 1986; Reisine and Jensen 1986). 
The mechanism by which CCK agonism releases ACTH 
has not yet been determined. There is some in vitro evidence 
that it is not mediated by CRH (Reisine and Jensen 1986). 
Our data are consistent with this possibility in that the 
ACTH response we observed is comparable in size but 
considerably more rapid than that seen in ~ to either 
human or ovine CRH (Bardeleben and Holsboer ! 988; Roy- 
Byrne et al 1986). Peak ACTH levels occur ~ 5 ~ of 
pentagastrin infusion but not until about 30 ~ after CRH 
infusion. Even when intensive effort is rp~de to insure v ~  
rapid infusion of a CRH bolus, ~ ~ does ~ appear 
until 10-15 min after infusion (Young et al 1990). T ~  
rapidity of the CCK-induced ACTH ~ is strikingly 
consistent across studies (Degfi Uberti et al 1983; Sl~th- 
Schwalhe et ai 1988) and clearly different from h ~  CRH 
even ~n direct comparison (Spiith-SchwMbe et al 1988). The 
'ack 3f a relationship in our data between ~ ACTH re- 
sponse to pentagastrin and baseline cortisol levels also dif- 
ferentiates CCK-mediated HPA activation from CRH-meo 
~liated actiw,tion and suggests that the CCK-mediated 
response may be relatively insensitive to cortisol feedback 
inhibition. In vitro, however, the CCK-induced response 
has been suppressible with dexamethasone, like CRH- 
stimulated ACTH release (Matsumu~ et al 1983; Reisine 
and Jensen 1986). The r e l i v e  sensitivity of the ~ o  activa- 
tors to glucocorticoid inhibition has not been directly exam- 
ined in animal models in vivo. Clarification of the roles of 
CRH and of cortisol feedback inhibition in CCK-induced 
HPA activation will require further study. 
Whether the ACTH response we observed is mediated by 
the CCK-B receptor also r e i n s  unknown. ~ evi- 
dence suggests that stimulation of the corticotroph by CCK 
is not mediated by either the CCK-A or CCK-B receptor, 
but may involve a third, novel CCK receptor subtype (Mat- 
sumura et al 1983; Reisine and Jensen 1986). Substantial 
cross-species variation in the central distribution and func- 
tion of the A and B receptor types (Woodruff et al 1991) 
makes it difficult to draw cross-species conclusions about 
CCK receptor subtype function, however. The intracellular 
mechanism by which CCK stimulates ACTH release is also 
not yet established but, in contrast to CRH, CCK-stimulated 
ACTH release does not appear to involve cyclic adenosine 
monophosphate (cAMP) (Reisine and Jensen 1986). 
HPA Axis and Panic Disorder 
Our data suggest that panic patients do not differ from 
norn~al control subjects in their ACTH or cortisol responses 
to pcntagastrin. Interpretation is com01icated by the effect 
of phase on HPA axis activity. Discussion of patient-con- 
trol comparisons in analyses that separate the two phases are 
speculative and preliminary, because cell sizes become 
quite small in these analyses. Phase 1 data did ~ise the 
possibility that patients had greater HPA response~ to pen- 
tagastrin, however, reflected in overall higher ACT.~ levels 
and greater postpentagasu'in cortisol secretion. Bec~use the 
elevated postpentagastrin cortisol levels could be due to 
elevated pre-infusion ACTH levels, it remained ~nclear 
whether patient-control differences reflected differ,. ~ nces in 
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responsivity to pentagastrin or in responsivity to the experi- 
mental situation. Phase 2 data suggests that it is more related 
to situational factors than to drug effects since patients and 
controls looked nearly identical when studied after prior 
experience in the experimental situation. For baseline 
ACTH secretion, placebo responses, and postpentagastrin 
ACTH secretion, differences between patients and controls 
appear~ only during the subjects' first experience in the 
CRC. This phase effect is consistent with other reports that 
panic patients are hyperresponsive to "novel" stimuli, such 
as laboratory situations (Roth et al 1992), and with evidence 
that the HPA axis is responsive to novelty stress (Breier et al 
1987; Davis et al 1981; Voigt et a11990; Young et al 1990). 
Apparent abnormalities in HPA axis activity in panic pa- 
tients could thus be due to a secondary response of the axis 
to, for example, an abnormality in an arousal/vigilance sys- 
tem that creates hypersensitivity to experimental situations, 
rather than a p r i m ~  pathophysiological defect within the 
HPA ~ i s  i~ l f .  Our evidence that pentagastrin is less ab- 
normally activating of the HPA axis in panic patients when 
they have had a prior benign experience in the experimental 
situation supports this possibili:y. Increased anticipatory 
anxiety in "novel" environments or situations could ac- 
count for many of the apparent HPA axis abnormalities thus 
far reported in panic patients (Abelson et al 1991; Cart et al 
1986; Goldstein et al 1987; Gurguis et al 1991; Nesse et al 
1984; Roy-Byme et al 1986). Basal elevations in ACTH 
levels, for example, appear more likely to be reported when 
they are measured just prior to first exposure to a complex 
procedure (Roy-Byme et al 1986) than when they are mea- 
sured after more prolonged exposure to th: laboratory situa- 
tion (Holsboer et al 1987) or in the context of a simple blood 
draw (Gurguis et al 1991). 
The strongest evidence for a more primary HPA axis 
abnormality comes from two reports of blunted ACTH re- 
sponses to CRH in panic patients (Holsboer et al 1987; 
Roy-Byrne et al i986), in one of these studies (Roy-Byme 
et al 1986), however, the blunted ACTH response could be 
secondary to situational factors. Baseline levels of ACTH 
and cortisol were elevated, perhaps due to an early secretory 
response to entry into the experimental situation. This acute 
stress response prior to the CRH challenge could then be 
responsible for the blunting following challenge, since both 
human (Young et al 1990) and animal data (Rivier and Vale 
1983; Young and Aki! 1985) suggest that acute stress can be 
followed by an acute subsensitivity of pituitary cortico- 
trophs to CRH challenge. The patient-control difference 
could therefore be due to events occurring before the infu- 
sion and not to differential responsivity to the CRH itself. 
This type of explanation applies less well to the CRH stimu- 
lation test data from the European group (Holsboer et al 
1987) as subjects in their setting had a 6-hr period of accom- 
modation to the laboratory situation, and the blood-drawing 
and infusion procedures were done out of view of the sub- 
jects. Perhapsthe reduced novelty and stressfulness of this 
paradigm accounts for the normal baseline levels of ACTH 
and cortisol seen, but ACTH responses to CRH remained 
blunted.. Unfortunately, this group's published reports (Bar- 
deleben and Holsboer 1988; Holsboer et al 1987) do not 
facilitate full assessment of the possible effects of situa- 
tional reactivity on their results. Procedures are not de- 
scribed in de~l .  Patients' responses to the accommodation 
phase and ACTH secretory activity during it are not re- 
ported and could account for some of the subsequent blunt- 
ing after CRH stimulation. 
Though the effects of novelty sensitivity on panic pa- 
tients' HPA responses to pentagastrin seemed clear in our 
data, follow-up studies explicitly designed to study this 
phenomenon are needed before definitive conclusions can 
be drawn. In retrospect it appeared to us that pentagastrin 
was given in a "high novelty/anticipatory anxiety" condi- 
tion in phase I but in a lower "novelty/anticipatory anxiety" 
condition in phase 2. The conditions were not explicitly 
designed to create differential levels of stress or anxiety and 
subjects were not randomly assigned to condition, however. 
If appropriately designed studies confirm that differential 
sensitivity to novelty stress can contribute to differential 
neuroendocrine responsivity when panic patients are com- 
pared to controls, then study of receptor level sensitivities 
using pharmacological probes in this patient population will 
be much more difficult. The circumstances under which a 
neuroendocrine response is measured may markedly affect 
results and levels of novelty and anticipatory anxiety will 
need to be carefully controlled and monitored. Panic pa- 
tients may need to be desensitized to the nonspecific stres- 
sors of the research setting before the pharmacological 
probe is applied if receptor level sensitivity to specific phar- 
macological effects of the probe are of primary interest. It 
was with this possibility in mind that we decided to use a 
fixed order, active-substance-second design in phase 2. The 
results suggest that this strategy may be appropriate in stud- 
ies of this sort. A randomized-order design in phase 2 may 
have led us to the erroneous conclusion that exaggerated 
cortisol responses to pentagastrin are present in panic. Our 
novelty-effect findings must, however, be considered pre- 
liminary. The ultimate appropriateness of fixed or random- 
ized order designs in neuroendocrine infusion studies in 
panic patients can only be determined by larger follow-up 
studies that utilize both designs to directly examine novelty 
effects. 
We believe that further development and utilization of 
pentagastrin as a probe of the stress axis in panic patients, 
including manipulation and closer monitoring of preinfu- 
sion situational stressors, could help illuminate the nature of 
the apparent HPA axis dysregulation seen in some studies of 
panic disorder. Test-retest paradigms will be needed to 
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examine the stability of the HPA response to pentagastrin 
over time and are especially important in light of panic 
patients' supersensitivity to first exposure effects. Further 
studies with CRH are also needed, but must include fuller 
descriptions of preinfusion activity in the axis. 
CCK and Other Systems 
The absence of GH response to pentagastrin in either pa- 
tients or controls highlights the pharmacological specificity 
of the ACTH response. The fact that our panic patients had 
significantly lower GH levels overall than controls also 
adds to the growing body of evidence that patients with 
panic disorder have a regulatory abnormality in their GH 
axis (Uhde et al 1992). Given the anxiety and subjective 
distress produced by pentagastrin (Abelson and Hesse 
1994), we might have expected some elevation in GH 
levels. There is both animal (Karashima et al 1984; Spencer 
et al 1991) and human data, however (Hair et al 1984), that 
suggest that CCK agonism can inhibit stimulated GH secre- 
tion. This raises the possibility that CCK might play a role in 
the consistently blunted GH response to clonidine seen in 
patients with panic disorder (Abelson et al 1992). Given that 
CCK agonism may play a role in anxiogenesis (Bradwejn et 
al i 991), the possibility that it may also inhibit GH secretion 
is extremely intriguing, as CCK could therefore play a role 
both in symptom production in panic disorder and in the 
most robust neuroendocrine abnormality thus far identified 
in panic patients. The animal data on the effects of CCK on 
GH are not entirely consistent with an inhibitory effect 
(Matsumura et al ! 984), but because of species variability in 
CCK function more human data is needed. Pentagastdn 
provides a useful tool to explore CCK-GH interactions in 
humans. Its ability to inhibit stimulated GH secretion in 
both normat controls and panic patients should be exam- 
ined, as should the ability of CCK antagonists to reverse the 
blunted GH response to cionidine seen in patients with panic 
disorder. 
The strong inverse relationship between baseline ACTH 
levels on pentagastrin infusion day and overall GH levels is 
intriguing. It suggests that those subjects whose HPA axes 
were most reactive to anticipation of the experimental pro- 
cedure had the greatest tonic inhibition in their GH axes. 
There is some evidence that CRH can in fact inhibit GH 
release in animals (Rivier and Vale 1984); and some human 
data suggest that HPA axis hormones can modulate GH 
release patterns (Wiedemann et al 1991). The overactivity 
of the HPA axis and underactivity in the HPS axis noted in 
some psychiatric disorders, including panic, may thus not 
represent entirely independent phenomena (Wiedemann et 
al 1991 ). Our data provide one of the first demonstrations of 
a correlation between increased HPA reactivity and de- 
creased HPS activity within a single group of panic patients. 
Discovery of the linkage mechanism could provide impor- 
rant new infonration on GH ar~l ~ ~ ~ i t i e s  in 
psychiatric disorders. ~ CCK appears ~ of 
both activating the HPA axis ~ ~ b i t i n g  GH release, ~ 
could mediate the link between the two systems. 
The brief but consistent epinephrine ~ ~ ~ 
quite intrigding. We unfortunately did not collect + 1 min 
samples in phase 2 so we do not know if it is a response to ~ 
pentagastrin or to the act of being infused. It appeared 
simultaneously with or just before the appearance of symp- 
toms but was not correlated with symptoms. Its rapidity, 
brevity, and consistency across subjects suggest that it way 
have been a first-pass pharmacol~cal response of the 
adrenal medulla to the CCK-B agonist. We are not aware of 
any studies examining ~ adrenal medulla for the presence 
of CCK-B receptors. The brevity of ~ response suggests 
that continuous sampling techniques may be critical for 
meaningful study ofcatecholamines in patients with anxiety 
disorders (Dimsdale and Moss 1980). 
Our data do not support the hypothesis that symptoms 
induced by peripheral release of vasoactive peptides such as 
NKA, VIP, or substance P might account for pentagastrin's 
panicogenic effects. The lack of peripherally detectable va- 
soactive peptide release may indicate that activity at or 
above the level of the p i t u i ~  is more relevant to the role of 
CCK in anxiety disorders than activity in the pedpbery. 
NKA, substance P, and VIP are ~ found in the central 
nervous system as well as pedpberally and all have actions 
and neuroendocrine interactions that make them of potential 
interest to psychoneuroendocrine research (Brodin et al 
1989; Gjerris et al 1984; Panza et al 1992; Reichlin 1988; 
Shen and North 1992; Tschope et al 1992). Our data shed 
little light on their possible relevance to panic disorder; but 
the rise in VIP following pentagastrin infusion and the asso- 
ciation between basal NKA and ACTH levels (raising the 
possibility that NKA is stress responsive) are findings that 
merit further exploration. Our data did provide a hint that a 
subset of patients might have elevated levels of substance P 
or VIP (data not presented), but there were too few subjects 
and too much variance to draw any real conclusions. Further 
study of these peptides in panic patients may still be 
warranted. 
Implications 
If follow-up studies support the hypotheses that CCK mod- 
ulates HPA axis activity independenti~ of CRH, via differ- 
ent intracellular mechanisms, and with differing sensitivity 
to glucocorticoid feedback inhibition, this would be of great 
theoretical interest to biological psychiatry. Multihormonal 
control of the HPA axis is clearly supported by available 
data and likely reflects the critical importance of the stress 
axis in mammalian adaptation (Axelrod and Reisine 1984). 
Multihormonal control of the axis may allow its continued 
responsivity to acute stressors even when chronic stress or 
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other factors may have reduced its responsivity to some 
activators (Reisine and Jensen 1986). CCK could partici- 
pate in acute stress axis activation in psychiatric patients 
who have reduced responsivity to CRH. Evidence that panic 
patients have normal ACTH responses to pentagastrin but 
blunted responses to CRH (Bardeleben and Holsboer 1988; 
Roy-Byme et al 1986) is consistent with this possibility, 
although other factors may be involved for panic patients 
(see above). Application of the pentagastrin stimulation test 
to other psychiatric disorders that demonstrate blunted 
ACTH responses to CRH will provide additional tests of 
this hypothesis. The possibility that psychiatric patients 
might have differing ACTH and cortisol responses to two 
ACTH secretogogues that work through differing mecha- 
nisms and with differing sensitivi~!e~ to feedback inhibition 
creates intriguing new avenues for study of stress axis regu- 
lation in these populations. The roles of hypercortisolemia 
or cAMP (Charney et a11989; Smith et al 1989) in HPA axis 
dysregulation, for example, could be explored using com- 
bined infusions of pentagastrin and CRH. 
Our data caution us to be careful about the conclusions we 
draw from neuroendocdne studies in patients with panic 
disorder because nonpharmacological aspects of experi- 
mental paradigms may influence endocrine responses to 
phramacological probes. An apparent abnormality in regu- 
lation of the HPA axis in panic patients (Holsboer et a11987; 
Roy-Byme et al 1986), for example, could be due to an 
References 
Abelson JL, Nesse RM ( ! 994): Pentagastrin infusions in patients 
with panic disorder I. Symptoms and cardiovascular responses. 
Biol Psychiat~, 36:73-83. 
Abelson JL, Nesse RM, Vinik A ( ! 991 ): Stimulation of corticotro- 
pin release by pentagastrin in normal subjects and patients with 
panic disorder. Biol P~'chiat~, 29:1220- ! 223. 
Abelson JL, Glitz D, Cameron OG, Lee MA, Bronzo M, Curtis GC 
l' ! 0 0 9 ) .  I : : n r l ~ n , ~  ,,,~.-A; . . . . . . . .  ! . . . .  ~a . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  ,,,,,., ~havioral responses to 
clonidine in patients with panic disorder. Biol Psychiat~ 
32:18-25. 
Ahlman H, Dahlstrom A, Gronstad K, et al (I 985): The pentagas- 
trin test in the diagnosis of the carcinoid syndrome. Blockade 
of gastrointestinal symptoms by ketanserin. Ann Surg 
201:81-6. 
Axelrod J, Reisine TD ( 1984): Stress hormones: Their interaction 
and regulation. Science 224:452--459. 
Baber NS, Dourish CT, Hill DR (1989): The role of CCK, caeru- 
lein, and CCK antagonists in nociception. Pain 39:307-328. 
Bardeleben U yon, Holsboer F (1988): Human corticotropin re- 
leasing hormone: Clinical studies in patients with affective 
disorders, alcoholism, panic disorder and in nolxnal controls. 
Prog Neuropsychopharmacol Biol Psychiatry 12:S 165-S 187. 
Beresford IJM, Hall MD, Clark CR, Hill RG, Hughes J (1988): 
Cholecystokinin modulation of [3H]noradrenaline release 
from supeffused hypothalamic slices. Neurosci Lett 88:227- 
232. 
interaction between an abnormality in arousal/attentional 
control systems (noradrenergic, locus coeruleus?) and ex- 
perimental situations rather than any intrinsic dysregulation 
within the HPA axis itself. 
Similarly, some have speculated that the sensitivity of  
panic patients to the anxiogenic capacity of  CCK could be 
due to increased sensitivity of the CCK-B receptor in pa- 
tients with panic disorder (Brambilla et al 1993). Nonphar- 
macological aspects of  the infusion experience could con- 
tribute to the patients' behavioral sensitivity, however. The 
normal neuroendocrine responses of  panic patients to pen- 
tagastrin argues against abnormal CCK-B receptor sensitiv- 
ity, though low dose infusion studies are needed before 
definitive conclusions about receptor sensitivity can be 
reached. 
Clearly much work remains to be done. An expanding 
collection of receptor-specific agonist and antagonist neur- 
oendocrine probes will greatly facilitate that work. Penta- 
gastrin is a useful addition to that collection, providing a 
safe and readily available tool for studying the psychoneur- 
oendocrinology of CCK-B receptor systems in humans. 
Special thanks to the CRC nurses for their skilled assistance in d_a~.am collec- 
tion; to T. W. Uhde, M.D. and D. E. Schteingart, , ~  for their assistance in 
completion of hormone assays; and m E. A. Young, MD and D. E. Schtein- 
gart for reviews of an earlier draft of the manuscript. 
Bradwejn J, Koszycki D, Shdqui C (i991): Erdaanced sensitivity 
to choiecystokinin tetrapeptide in panic disorder. Arch Gen 
Ps3,chiat~. 48:603-610. 
Bradwejn J, Koszycki D, Dutertre AC, et al (1993): L-365,260, a 
CCK-B antagonist, blocks CCK-4 in panic disorder. Presented 
at Anxiety Disorders Association of America Annual Meeting, 
Charleston, South Carolina, March 20, 1993. 
Brambiiia F, Bellodi L, Pema G, Garberi A, Panerai A, Sacerdote 
P ( ! 993): Lymphocyte cholecystokinin concentrations in panic 
disorder. Am J Psychiatry 150:111 l - !  ! 13. 
Breier A, Albus M, Pickar D, Zahn TP, Wolkowitz OM, Paul SM 
(1987): Controllable and uncontrollable stress in humans: Al- 
terations in mood and neuroendocrine and psychophysiologi- 
cal function. Am J Psychiatry ! 44:1419-1425. 
Breier A, Wolkowitz OM, Doran AR, Bellar S, Pickar D (1988): 
Neurobiological effects of lumbar puncture stress in psy- 
chiatric patients and healthy volunteers. Psychiatry Res 
25:187-94. 
Brodin K, Rosen A, Iwarsson K, Ogren SO, Brodin E (1989): 
Increased levels of substance P and cholecystokinin in rat cere- 
bral cortex following repeated electroconvulsive shock and 
subchronic treatment with a serotonin reuptake inhibitor. Acta 
Physiol Scand 136:6 ! 3-614. 
Carr DB, Sheehan DV, Surman OS, et al (1986): Neuroendocrine 
correlates of lactate-induced anxiety and their response to 
chronic alprazolam therapy. Am J Psychiatry 143:483-494. 
Responses to Pentagastrin in Panic at¢~ ~¥CHt~Y 95 
1994~:84~96 
Chamey DS, Innis RB, Duman RS, Woods SW, Heninger GR 
(1989): Platelet alpha-2-receptor binding and adenylate cy- 
clase activity in panic disorder. Psychopharmacology (Bed) 
98:102-107. 
Crawley JN (1991): Cholecystokinin-dopamine interactions. 
Trends Pharmacol Sci 12:232-236. 
Davis HA, Gass GC, Bassett JR (! 981): Serum cortisol response to 
incremental work in experienced a~d naive subjects. Psycho- 
sore Med 43:127-132. 
de Montigny C (1989): Cholecystokinin tetrapeptide induces 
panic-fike attacks in healthy volunteers. Arch Gen Psychiatry 
46:511-517. 
Degli Uberti EC, Transforini G, Margutti AR, Rotola CA, Pansini 
R (1983): Effect of pentagastrin on adrenocorticotropin hor- 
mone and thyroid-stimulating hormone release in normal sub- 
jects. Horm Res 17:74-77. 
Dethloff LA, De La lglesia FA (1992): Cholecystokinin antago- 
nists--A toxicologic perspective. Dn~g Metab Rev 24:267- 
293. 
Dimsdale JE, Moss J (1980): Short-term catecholamine response 
to psychological stress. Psychosom Med 42:493-497. 
Gjerris A, Rafaelsen O J, Vendsborg P, Fahrenkrug J, Rehfeld JF 
(1984): Vasoactive intestinal peptide decreased in cerebro- 
spinal fluid (CSF) in atypical depression. J Affective Disord 
7:325-337. 
Goldstein S, Halbreich U, Asnis G, Endicott J, Alvir J ( 1987): The 
hypothalamic-pituitary-adrenal system in panic disorder. Am 
J Psychiatry 144:1320-1323. 
Gurguis GNM, Mefford IN, Uhde TW (1991): Hypothalamic- 
pituitary-adrenocortical activity in panic disorder: Relation- 
ship to plasma catecholamine metabolites. Biol Psychiato, 
30:502-506. 
Holsboer F, Bardeleben U yon, 3uiler R, Heuser I, A S ( 1987): 
Stimulation response to corticotropin-releasing hormone 
(CRH) patieats in with depression, alcoholism and panic dis- 
order. Horm Metab Res [suppl] 16:80-88. 
Hughes J, Hunter JC, Woodruff GN (1991): Neurochemical ac- 
tions of CCK underlying the therapeutic potential of CCK-B 
antagonists. Neuropeptides 19(suppl):85-89. 
Kaneyuk_i T~ Mo_rim~a T, Shohmori T ( !989): Action of peripher- 
ally administered cholecystokinin on monoaminergic and 
GABAergic neurons in the rat brain. Acta Med Okavama 
43:153-159. 
Karashima T, Okajima T, Kato K, Ibayashi H ( ! 984): Suppressive 
effects of cholecystokinin and bombesin on growth hormone 
and prolactin secretion in urethaneanesthetized rats. Endo- 
crinol Jpn 31:539-47. 
Kulkosky PJ, Sanchez MR, Foderaro MA, Chiu N ( 1989): Chole- 
cystokinin and satiation with alcohol. Alcohol 6:395-402. 
Larsson LI, Rehfeld JF (198 l): Pituitary gastrins occur in cortico- 
trophs and melanotrophs. Science 213:768-770. 
Matsumura M, Yamanoi A, Yamamoto S, Saito S ( 1983): In vivo 
and in vitro effects of cholecystokinin octapeptide on the re- 
lease of ~3-endorphin-like-immunoreactivity. Neuroendocrin- 
ology 36:443-448. 
Matsumura M, Yamanoi A, Yamamoto S, Mori H, Saito S ( 1984): 
In vivo and in vitro effects of cholecystokinin octapeptide on 
the release of growth hormone in rats. Honn Metab Res 
16:626-630. 
Mezey E, Reisine TD, Skirboll L, Beinfeld M, Kiss ~ (1986): 
Role of cholecystokinin in corticotropin release: Coexistence 
with vasopressin and corticotropin-releasing factor in cells of 
the ~at hypothalamic pa~-aventricular nucleus. Proc Nail Acad 
Sci 83:351 0-3512. 
Nair NP, Lal S, Thavundayil JX, Wood PL, Etierme P, Guyda H 
(1984): CCK-33 an~gonizes apomorphine-induced growth 
hormone secretion and increases ~ prolactin levels in re.an. 
Neuropeptides 4:281-91. 
Nesse RM, Cameron OG, Curtis GC, McCann DS, Huber-Smith 
MJ ( 1984): Adrenergic function in l~tients with panic anxiety. 
Arch Gen Psychiatry 41:771-776. 
Oberg K, Norheim I, Theodorsson E, Ahlman H, Lundqvist G, 
Wide L (1989): The effects of octreotide on basal and stimu- 
lated hormone levels in patients with carcinoid syndrome. J 
Clin Endocrinol Metab 68:796-800. 
O'Connell JE, Dominiczak AF, Isles CG, et al ( 1990): A compari- 
son of calcium pentagastrin and TRH tests in screening for 
medullary carcinoma of the thyroid in MEN IIA. Clin Endo- 
crino132:417-421. 
Panza G, Monzani E, Sacerdote P, Penati G, Panerai AE (1992): 
Beta-endorphin, vasoactive intestinal peptide and cholecysto- 
kinin in peripheral blood mononuclear cells from healthy sub- 
jec~s and from drug-free and haloperidol-treated schizophrenic 
patients. Acta Psychiatr Scand 85:207- I 0. 
Rehfeld ~F ( 1978): Localization of gasu'ins to neuro-- and adenohy- 
pophysis. Nature ( Lond) 271:771-773. 
Rehfeld JF (1985): Neuronal ch~I~cystokinin: one or multiple 
transmitters? J Neurochen~ .d4 :1-10. 
Rehfeld .IF, Larsson LI (1981): Pituitary gastrins: Different pro- 
cessing in corticotrophs and melanotrophs. J Biol Chem 
256:10426-10429. 
Rehfeld JF, Lindholm J. A:.".,c,'sen BN, Bardram L, Cantor P, 
Fenger M, Ltidecke DK (1987): Pituitary tumors containing 
cholecystokinin. N Engl J Med 316: ! 244-1247. 
Reichlin S (1988): Neuroendocrine significance of vasoactive in- 
testinal polypeptide. Ann NYAcad Sci 527:431 A.~A9. 
Reisine T, Jensen R (1986): Cholecystokinin-8 stimulates adreno- 
corticotropin release from anterior pituitary cells. J Pharmacol 
Exp Ther 236:621-626. 
Rivier C, Vale W (1983): Influence of the frequency of ovine 
corticotropin releasing factor administration on adrenocortico- 
tropin and corticosterone secretion in rat. Endocrinology 
I 13:1422-1426. 
Rivier C, Vale W (1984): Ovine corticotropin releasing factor 
(CRF) acts centrally to inhibit ~owth hormone secretion in the 
rat. Endocrinology 114:2409-2411. 
Roth WT, MargrafJ, Ehlers A, et al ( 1992): Stress test reactivity in 
panic disorder. Arch Gen Ps.vchiato" 49:301-310. 
Roy-Byrne PP, Uhde TW, Post RM, Gallucci W, Chrousos GP, 
Gold PW ( 1986): The corticotropin-releasing hormone stimu- 
lation test in patients with panic disorders. Am J Psychiato' 
143:896-899. 
Sheehan M J, de Belleroche J ( 1983): Facilitation of GABA release 
by cholecystokinin and caerulein in rat cerebral cortex. Neuro- 
peptides 3:429-434. 
Shen KZ, North RA (1992): Substance P opens cation channels 
and closes potassium channels in rat locus coeruleus neurons. 
Neuroscience 50:345-354. 
~ BIOL PSYCHIATRY J.L. Abelson el al 
1994;36:84-96 
Silver AJ, Morley JE (1991): Role of CCK in regulation of food 
intake. Prog Neurobio136:23-34. 
Singh L, Lewis AS, Field MJ, Hughes J, Woodruff GN (1991): 
Evidence for an involvement of the brain cholecystokinin B 
receptor in anxiety. Proc Natl Acad Sci USA 88:1130-1133. 
Smith MA, Davidson J, Ritchie JC, et al ( 1989): The corticotropin- 
releasing hormone test in patients with posttraumatic stress 
disorder. Biol Psychiatry 26:349-355. 
Spath-Schwalbe E, Piroth L, Pietrowsky R, Born J, Lorenz Fehm 
H (1988): Stimulation of the pituitary adrenocortical system in 
man by cerulein, a cholecystokinin-8-1ike peptide. Clin Physiol 
Biochem 6:316-320. 
Spencer GS, Berry C, Johnston S (1991): Neuroendocrine regula- 
tion of growth hormone secretion in sheep. IV. Central and 
peripheral cholecystokinin. Domest Anita Endocrinoi 8:555- 
563. 
Spitzer RL, Williams JBW (1986): Structured Clinical Interview 
for DSM-III-R-Upjohn Version-Revised. Biometrics Research 
Department, New York State Psychiatric Institute. 
Stallone D, Nicolaidis S, Gibbs J (1989): Cholecystokinin-in- 
duced anorexia depends on seritoninergic function. Am J Phy- 
sio1256:R 1138-1141. 
Tschope C, Picard P, Culman J, et al (1992): Use of selective 
antagonists to dissociate the central cardiovascular and behav- 
ioral effects of tachykinins on NK 1 and NK2 receptors in rat. 
Br J Pharmacol 107:750-755. 
Uhde TW, Tancer ME, Rubinow DR, et al (1992): Evidence for 
hypothalamic-growth hormone dysfunction in panic disorder: 
profile of growth hormone (GH) responses to clonidine, yo- 
himbine, caffeine, glucose, GRF and TRH in panic disorder 
patients versus healthy volunteers. Neuropsychopharmacol. 
ogy 6:101-118. 
Vanderhaeghen JJ, Goldman S, Lotstra F, et al (1985): Co-exis- 
tence of cholecystokinin- or gastrin-like peptides with other 
peptides in the hypophysis and hypothalamus. Ann NY Acad 
Sci 448:334-344. 
Vinik AI, Gonin J, England BG, Jackson T, McLeod MK, Cho K 
(1990): Plasma substance-P in neuroendocrine tumors and 
idiopathic flushing: the value of pentagastrin stimulation tests 
and the effects of somatostatin analog. I Clin Endocrinol 
Metab 70: ! 702-9. 
Voigt K, Ziegler M, Gr0nert-Fuchs M, Bickel U, Fehm-Wolfsdorf 
G (1990): Hormonal responses to exhausting physical exer- 
cise: The role of predictability and controllability of the situa- 
tion. Psychoneuroendocrinology ! 5: ! 73-184. 
Wiedemann K, yon Bardeleben U, Holsboer F (i 99 !): Influence of 
human corticotropin-releasing hormone and adrenoconicotro- 
pin upon spontaneous growth hormone secretion. Neuroendo- 
crinology 54:462-468. 
Woodruff GN, Hughes J (1991): Cholecystokinin antagonists. 
Annu Rev Pharmacol Toxicol 31:469-501. 
Woodruff GN, Hill DR, Boden P, Pinnock R, Singh L, Hughes J 
( 1991 ): Functional role of brain CCK receptors. Neuropeptides 
19[suppl]:45-56. 
Young EA, Akil H (1985): CRF stimulation of ACTH/fl-endor- 
phin release: effects of acute and chronic stress. Endocrinology 
117:23. 
Young EA, Watson SJ, Kotun J, et al (1990): lS-Lipotmpin-[3- 
endorphin response to low-dose ovine corticotmpin releasing 
factor in endogenous depression.Arch Gen Psychiatry 47:449- 
457. 
